冠心病、高血压患者血浆P物质水平的临床观察

Clinical Study of Plasma SP Level in Patients with Coronary Heart Disease and Essential Hypertension

选择符合WHO诊断标准的急性心肌梗塞（AMI）患者20例、心绞痛（AP）患者30例、高血压病（EH）患者30例，应用放射免疫分析动态观察血浆P物质（SP）含量变化，并以30名正常人作为对照。结果显示：对照组SP水平为126．99±15．96pg／mL；AMI组发病第1天SP含量为62．85±16．76pg／mL，显著低于对照组（P＜0．01）。发病第7天开始升高至72．60±15．20pg／mL，第21天趋于正常，为110．10±27．95pg／mL，与对照组比较无显著差异（P＞0．05）。AP组心绞痛发作期SP含量为48．38±12．92pg／mL．显著低于对照组（P＜0．001），经治疗2周症状缓解后复查，血浆SP含量升高至78．70±9．15pg／mL，前后比较有显著差异（P＜0．001）。EH组SP含量为59．75±17．89pg／mL，明显低于对照组（26．99±15．96pg／mL，P＜0．001）；而且EH的病情越严重，血浆SP的含量降低越明显。提示：循环血中SP含量不足可能是引发冠心病（CHD）、EH的重要因素之一；SP参与了CHD及EH的发病机理及病理生理过程。

The changes of plasma substance P (SP) level were observed by RIA in 20 patients with acute myocardial infarction (AMI), 30 with angina pectoris (AP) and 30 with essential hypertension (EH). The plasma SP level was 126. 99 i 15. 96 pg/mL in the normal controlgroup (30 healthy persons), whereas it was 62. 85 ±16. 76pg/mL in AMI patients during thefirst day of onset (P < 0. 01 ). It began to increase from day 7 and reached the normal value atday 21 (110. 10 ± 27. 95pg/mL). The plasma SP level was 48. 38±12. 92pg/mL in AP patientsduring angina attack and was significantly lower than that of the normal group(P<0.001 ). After two weeks treatment, it increased to 78. 70 ± 9. 15pg/mL(P< 0.001). The plasma SP levelwas 59. 75±17. 89pg/mL in patients with EH and was significantly lower than that of the normalgroup(P<0.001 ). It was found that the increase of plasma SP level was closely related with theseventy of hypertension. It is suggested that the decrease of plasma SP level may play an important role in pathogenesis of coronary heart disease and EH.